For Immediate Release September 29, 2021 MSSNY Applauds Gov. Hochul’s Appointment of Mary Bassett, MD, MPH as NYS Department of Health Commissioner Statement Attributable to: Joseph R. Sellers, MD, FAAP, FACP President, Medical Society of the State of New York “MSSNY is thrilled to welcome Dr. Mary Bassett as New York State’s new Health
For Immediate Release September 28, 2021 AMA, MSSNY Strongly Support Governor Hochul’s Efforts to Require Health Care Workers to be Vaccinated Against COVID-19 Statement Attributable to: Joseph R. Sellers, MD, FAAP, FACP President, Medical Society of the State of New York Gerald E. Harmon, M.D. President, American Medical Association “The American Medical Association (AMA)
Dear COVID-19 Vaccination Provider: On September 24, 2021, under the U.S. Food and Drug Administration’s (FDA) updated emergency use authorization (EUA), the CDC issued recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine at least six months after completion of the primary series for the following individuals: individuals 65 years of age and older, and
Pfizer-BioNTech COVID-19 Vaccine Licensure and Expiration Extension Dear COVID-19 Vaccination Provider, The FDA granted full licensure for Pfizer's COVID-19 vaccine on August 23, 2021. The full licensure applies to the use of this vaccine in the 16+ population. The vaccine also continues to be available under emergency use authorization (EUA) for adolescents 12 through 15 years of age and
Janssen/Johnson & Johnson COVID-19 Vaccine Expiration Extension On July 29, 2021, the U.S. Food & Drug Administration (FDA) authorized an extension of the shelf life for the Janssen/Johnson & Johnson (J&J) single-shot COVID-19 vaccine by 45 days, from 4.5 months to 6 months. The decision is based on data from ongoing stability assessment studies, which have
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS) after administration of the vaccine.
Dear COVID-19 Vaccination Program Provider: This message is being sent to all COVID-19 Vaccination Program enrolled providers in an effort to increase vaccinated individuals’ ability to obtain an Excelsior Pass. If you have not yet administered COVID-19 vaccine, you may disregard this message. Excelsior Pass mobile application is New York State’s voluntary and secure way
For Immediate Release June 15, 2021 New York State Reaches 70 Percent Adult COVID-19 Immunization Governor’s Vaccine Distribution and Implementation Task Force Member and NYS Medical Society Immediate Past President Reflects on Reaching Important Milestone and Calls for Continued Vaccination Efforts Statement from Bonnie Litvack, MD Immediate Past President, Medical Society of the State of New
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS) after administration of the vaccine.
Dear Enrolled Provider: Effective today, May 11th, New York State is moving to a “Universal Dose” administration process for all multi-dose COVID-19 vaccine types. All doses are now considered universal doses, which means that doses can be used for a first dose or a second dose, irrespective as to whether they were originally shipped to providers as a first dose or a second dose. First and
